Literature DB >> 6610349

Progression of atherosclerosis in coronary arteries and bypass grafts: ten years later.

M G Bourassa, M Enjalbert, L Campeau, J Lesperance.   

Abstract

Progression of atherosclerosis in aortocoronary saphenous vein grafts is frequent and is the predominant cause of late graft closure after CABG. Only approximately 60% of grafts remain patent between 10 and 12 years after surgery. Of patent grafts, 45% show angiographic evidence of atherosclerosis between 10 and 12 years after surgery and 70% of the atherosclerotic lesions reduce the graft lumen diameter by 50% or more. Atherosclerosis of saphenous vein grafts does not appear to be related to age, sex or cigarette smoking, but is associated with abnormalities of cholesterol lipoprotein fractions. Progression of atherosclerosis in the native coronary arteries is also very significant after CABG. Progression of CAD between 10 and 12 years after surgery occurs in approximately 50% of nongrafted arteries. Between 10 and 12 years after surgery, the rate of progression of disease in nongrafted arteries is not different from that of grafted arteries with patent grafts; however, progression is more frequent in grafted arteries with occluded grafts. The rate of progression is not related to age, sex, risk factors or extent of disease at baseline coronary arteriography. Progression of preexisting stenoses is more frequent than appearance of new stenosis. Progression is related to the severity of the preexisting stenosis only in nongrafted arteries. Finally, progression is related to alterations of left ventricular function during follow-up. Because of these progressive late changes, CABG should probably remain limited to patients with incapacitating anginal symptoms or to those with severe lesions for whom surgery might enhance long-term survival, such as patients with severe left main CAD and 3-vessel CAD.

Entities:  

Mesh:

Year:  1984        PMID: 6610349     DOI: 10.1016/0002-9149(84)90759-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  Anesthesia and myocardial infarction.

Authors:  J G Maillé; M Boulanger; I Dyrda; N Trembly
Journal:  Can Anaesth Soc J       Date:  1986-11

2.  Saphenous vein graft near-infrared spectroscopy imaging insights from the lipid core plaque association with clinical events near-infrared spectroscopy (ORACLE-NIRS) registry.

Authors:  Barbara A Danek; Aris Karatasakis; Aya J Alame; Phuong-Khanh J Nguyen-Trong; Judit Karacsonyi; Bavana Rangan; Michele Roesle; Amy Atwell; Erica Resendes; Jose Roberto Martinez-Parachini; Rahel Iwnetu; Pratik Kalsaria; Furqan Siddiqui; James E Muller; Subhash Banerjee; Emmanouil Brilakis
Journal:  Catheter Cardiovasc Interv       Date:  2016-08-18       Impact factor: 2.692

3.  "Topical" HDL for vein grafts: a new solution to an old problem?

Authors:  Reto Asmis
Journal:  Atherosclerosis       Date:  2010-11-23       Impact factor: 5.162

4.  Effects of therapy with diet and simvastatin on atherosclerosis in hypercholesterolemic patients.

Authors:  C W Barlow; B M Friedman; D P Myburgh; E R Soicher; W F Steenkamp; D H Smith
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

5.  Clinical and angiographic acute and follow up results of intracoronary beta brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European registry of intraluminal coronary beta brachytherapy (RENO).

Authors:  T M Schiele; E Regar; S Silber; E Eeckhout; D Baumgart; W Wijns; A Colombo; W Rutsch; D Meerkin; A Gershlick; R Bonan; P Urban
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

6.  Measures to increase the number of mammary artery coronary artery anastomoses.

Authors:  A J Tector; T M Schmahl; V R Canino
Journal:  Tex Heart Inst J       Date:  1986-03

7.  A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Authors:  Olivier F Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

8.  Clinical characteristics and outcomes of patients with acute coronary syndrome and prior coronary artery bypass grafting in a large middle eastern cohort.

Authors:  Muath Alanbaei; Alawi A Alsheikh-Ali; Tareq Aleinati; Mohammad Zubaid; Mustafa Ridha; Fahad Alenezi; Wael Al-Mahmeed; Kadhim Sulaiman; Jawad Al-Lawati; Haitham Amin; Jassim Al Suwaidi; Ahmed Al-Motarreb
Journal:  Open Cardiovasc Med J       Date:  2011-08-30

9.  A pilot randomized controlled trial comparing CABG surgery performed with total arterial grafts or without.

Authors:  Jeffrey Le; Roger J F Baskett; Karen J Buth; Gregory M Hirsch; Allan Brydie; Ryan Gayner; Jean-Francois Legare
Journal:  J Cardiothorac Surg       Date:  2015-01-08       Impact factor: 1.637

10.  Long-term outcomes of percutaneous coronary intervention in grafts and native vessels in coronary artery bypass grafting patients with diabetes mellitus.

Authors:  Dong Liu; Xiao Cui; Xiaoliang Luo; Zhongwei Sun; Bo Xu; Shubin Qiao; Jiansong Yuan
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.